Clinical Trials Of MVA-EBNA1/LMP2, A Therapeutic Cancer Vaccine Designed To Treat Epstein-Barr Virus (EBV) Positive NasopharyngealCarcinoma (NPC)


Session type:

Neil Steven1,6, Kevin Harrington2, Lip Lee3, Edwin Hui9, Hui Jia1, David Price4, Kristin Ladell4, James Turner1, Manjit Tanday1, Claudia Roberts6,1, Ceri Edwards5, Lesley McGuigan5, Andrew Hartley6, Stephen Wilson7, Benjamin Johnson8, Anthony Chan9, Alan Rickinson1, Graham Taylor1
1School of Cancer Sciences, The University of Birmingham, Birmingham, England, UK,2Department of Cancer Biology, Institute of Cancer Research, London, England, UK,3Department of Clinical Oncology, The The Christie NHS Foundation Trust, Manchester, England, UK,4Institute of Infection and Immunity, Cardiff University School of Medicine, Cardiff, Wales, UK,5Drug Development Office, Cancer Research UK, London, England, UK,6University Hospital Birmingham NHS Foundation Trust, Birmingham, England, UK,7Health Protection Agency, West Midlands Public Health Laboratory, Birmingham, England, UK,8Section of Virology, Imperial College, London, England, UK,9The Chinese University of Hong Kong, Hong Kong Special Administrative Region, China



Most nasopharyngeal carcinoma (NPC) carry Epstein-Barr Virus (EBV) and consistently express two viral proteins, EB nuclear antigen 1 (EBNA1) and latent membrane protein 2 (LMP2). These proteins represent ideal targets for immunotherapy. MVA-EBNA1/LMP2 is an attenuated poxvirus-based therapeutic cancer vaccine designed to boost T cell immunity to these EBV-encoded tumour antigens in NPC patients.